UK developer of medical cannabis products raises $345million

UK biopharmaceutical company GW Pharmaceuticals, a global developer of medical cannabis products, released 2.1 million shares on the US stock exchange. The release of shares follows its work to receive marketing authorisation from the European Medicines Agency for another CBD product, joining the approved Epidiolex.